LOGIN  |  REGISTER
Amneal Pharmaceuticals
Terns Pharmaceuticals

Elanco Animal Health to Participate in the Bank of America 2023 Animal Health Summit

February 23, 2023 | Last Trade: US$18.55 0.48 -2.52

GREENFIELD, Ind. / Feb 23, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Bank of America 2023 Animal Health Summit on Thursday, March 2, 2023. Jeff Simmons, president and CEO, and Todd Young, executive vice president and CFO, will represent the company and respond to questions from analysts at 4:40 p.m. ET.

A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website. A replay will be available for approximately 30 days.

ABOUT ELANCO

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability Pledges –all to advance the health of animals, people, and the planet. Learn more at elanco.com.

Chimerix

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page